Related Experiment Video
Updated: Aug 12, 2026
A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
Published on: May 15, 2019
Dexamethasone for the treatment of depression: a preliminary report
1Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425-0742.
Insights
Intravenous dexamethasone shows promise for treating depression. This study found significant symptom reduction in depressed patients, suggesting glucocorticoids may be effective for depressive illnesses.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroendocrinology
Background:
- Investigates the potential of glucocorticoids, specifically intravenous dexamethasone, for treating depression.
- Addresses the need for novel therapeutic approaches in managing depressive disorders.
Purpose of the Study:
- To evaluate the efficacy of intravenous dexamethasone in reducing depressive symptoms.
- To determine if dexamethasone has a mood-altering effect in non-psychiatric individuals.
Main Methods:
- A preliminary, uncontrolled trial involving patients diagnosed with major depression or bipolar disorder (depressed type).
- Hamilton Rating Scale for Depression (HAM-D) scores were assessed before and within 10 days after dexamethasone infusion.
- Control subjects without psychiatric illness received dexamethasone to assess mood-altering effects.
Main Results:
- A 56% mean reduction in HAM-D scores was observed in 16 depressed subjects post-treatment (p < .0001).
- 75% of patients achieved over a 50% reduction in HAM-D scores.
- Non-psychiatric controls showed no significant changes in mental status after dexamethasone administration.
Conclusions:
- Intravenous dexamethasone may represent a viable treatment option for depressive illnesses.
- Further rigorous, controlled studies are necessary to confirm these findings and establish the validity of dexamethasone as a depression treatment.
Background:
This preliminary uncontrolled trial of intravenous dexamethasone addresses the question of the utility of a glucocorticoid for the treatment of depression.
Method:
Patients with a DSM-III-R (SCID confirmed) diagnosis of major depression or bipolar disorder, depressed type, and a Hamilton Rating Scale for Depression (HAM-D) score of greater than or equal to 20 were selected. Baseline HAM-D scores were compared with scores within 10 days after intravenous infusion of dexamethasone; data were analyzed by t tests. Control subjects (no psychiatric illness and HAM-D scores less than 5) were given intravenous dexamethasone to test for its mood-altering effect.
Results:
The mean HAM-D scores in 16 depressed subjects 10 days after intravenous dexamethasone dropped by 56% (p less than .0001), and 75% of the patients experienced a greater than 50% reduction in HAM-D scores. Additionally, 6 nonpsychiatric, nondepressed control subjects were given intravenous dexamethasone and found to have no changes in mental status examination.
Conclusions:
Intravenous dexamethasone may be an effective treatment for depressive illnesses. Because this was an uncontrolled, unblinded trial, further studies need to be done in nonpsychiatric and psychiatric controls to ascertain the validity of this finding.
More Related Videos
Related Concept Videos
01:54The Placebo Effect
01:18Depression: Overview
01:25Antidepressant Drugs: Overview
01:23Antidepressant Drugs: MAOIs and Other Agents
01:30Electroconvulsive Therapy